Tenpoint Therapeutics Ltd.

Sofinnova Partners\' latest fundraising haul brings the firm’s assets under management to more than 4 billion euros ($4.2 billion).\n Up to 60 new life sciences companies are set to benefit from 1.2 billion euros ($1.27 billion) that Sofinnova Partners has raked in over the past year, the European venture capital firm has announced.Sofinnova Partners—not to be confused with its U.S.-based “cousin” Sofinnova Investments—employs more than 80 people spread across its Paris headquarters as well as offices in London and Milan. The latest fundraising haul brings the firm’s assets under management to more than 4 billion euros ($4.2 billion).“All seven of Sofinnova’s investment strategies—from incubation to later-stage growth, spanning biotech, medtech, industrial biotech and digital medicine—have capital to back the next generation of life sciences companies,” Antoine Papiernik, Sofinnova Partners’ chairman and managing partner, said in a March 4 release.“With the new funds, we anticipate supporting 50 to 60 new companies, empowering a new wave of entrepreneurs tackling some of the world’s most pressing health and sustainability challenges,” Papiernik added. The firm’s portfolio of over 500 companies it has backed since its creation in 1972 have been spread across seven segments including biotech, medtech and digital medicine. Sofinnova said today it will share more details on its individual funds once they have closed.Some Sofinnova-backed success stories so far this year have included Mediar Therapeutics’ idiopathic pulmonary fibrosis licensing deal with Eli Lilly and a phase 3 win for Tenpoint Therapeutics’ presbyopia treatment.The second half of 2024 saw some big hauls across biotech investment, with Bain Capital Life Sciences and Arch Venture Partners both announcing biotech- and healthcare-focused VC funds of around $3 billion. Forbion also unveiled its largest haul to date in October, as the European life-sciences-focused VC firm brought in more than 2 billion euros across two funds.Last year, Maina Bhaman, a partner at Sofinnova, appeared on Fierce’s \"The Topline\" podcast to share her insights on how investors are approaching the European biotech sector. 

In its 53 year history, Sofinnova Partners has invested in more than 500 companies. The venture capital firm now has €1.2 billion to invest in more. The additional funds have come at a fast clip. Paris-based Sofinnova said Tuesday that more than €1 billion of the new capital was secured in the last quarter. The firm’s assets under management now top €4 billion. Sofinnova breaks out its investments into seven categories, which it calls investment strategies. These strategies span areas such as biotech, medtech, and digital medicine. Sofinnova has invested in companies such as vision disorders biotech Tenpoint Therapeutics and neurodegenerative disease-focused Asceneuron. Exclusive Improving the Healthcare Financial Experience to Help Care Flow Zelis CEO Amanda Eisel shares her perspective on how the company is solving the problems of a fragmented health financial system to benefit all. By Stephanie Baum The firm did not say how much money was going to each of its strategies, adding that details on individual funds will be disclosed upon their final closings. The money is coming from institutional investors, sovereign wealth funds, corporations, and family offices. “With the new funds, we anticipate supporting 50 to 60 new companies, empowering a new wave of entrepreneurs tackling some of the world’s most pressing health and sustainability challenges,” Chairman and Managing Partner Antoine Papiernik said in a prepared statement. In a report detailing the outlook for healthcare and life sciences in 2025, Pitchbook said venture investment will be defined by fewer but larger deals and funds. Macroeconomic pressures are accelerating this trend. Interest rates remain high and credit markets are tight, constraining the availability of venture capital, the report said. That prompts investors to prioritize de-risked opportunities. “Investors are gravitating toward late-stage companies with strong clinical validation, scalable technologies, and a clear path to monetization through licensing or acquisitions,” Pitchbook said in the report. “This shift is particularly evident in the rise of average deal sizes, which have increased as funding concentrates on fewer, high-impact opportunities.” Sponsored Post Mayo Clinic Platform Program to Help Clinical Digital Health Startups Succeed Mayo Clinic has developed a new tool that could speed up the time it takes for digital health companies to validate their tech to hospitals. By Mayo Clinic Platform Sofinnova isn’t the only European VC firm raking in new capital to deploy across fresh investments. Last October, Netherlands-based Forbion announced it had raised more than €2 billion for two funds, bringing its assets under management to €5 billion. By exceeding its fundraising targets, Forbion said it will be able to increase the number of investments and the size of the investments. The firm said the two funds will invest in about 15 new companies. Forbion co-led the $411 million Series A round announced in January for Verdiva Bio, a biotech advancing to Phase 2 testing with an oral GLP-1 obesity drug.

药械追踪 No.1 / 石药集团2型糖尿病新药普卢格列汀获NMPA批准 2025年1月10日，中国国家药品监督管理局（NMPA）宣布批准石药集团（1093.HK）1类创新药普卢格列汀片（商品名：善泽平）上市，该药适用于改善成人2型糖尿病患者的血糖控制。 普卢格列汀片是一种新型口服二肽基肽酶-IV（DPP-4）抑制剂，对DPP-4具有高选择性和强抑制性。通过抑制DPP-4，使内源性活性胰高血糖素样肽-1（GLP-1）水平升高从而增强β细胞和α细胞对葡萄糖的敏感性，增加葡萄糖刺激的胰岛素分泌并增强葡萄糖对胰高血糖素分泌的抑制作用，进而降低血糖水平且不诱发低血糖和增加体重。临床研究显示该产品具有持久的降糖作用且不良反应发生率较低，将为2型糖尿病患者的治疗提供更多选择。 ->点击文末阅读原文，解锁完整双语新闻 No.2 / 默沙东PD-1抑制剂可瑞达获NMPA批准扩展头颈鳞癌一线治疗适用人群 2025年1月13日，默沙东宣布，PD-1抑制剂帕博利珠单抗（商品名：可瑞达）已获得中国国家药品监督管理局（NMPA）批准，单药用于通过充分验证的检测评估肿瘤表达PD-L1（综合阳性评分[CPS]≥1）的转移性或不可切除的复发性头颈部鳞状细胞癌患者的一线治疗。此前，NMPA于2020年12月批准帕博利珠单抗单药用于通过充分验证的检测评估肿瘤表达PD-L1（综合阳性评分[CPS]≥20）的转移性或不可切除的复发性头颈部鳞状细胞癌患者的一线治疗。 可瑞达2018年在华首次获批，截至目前，可瑞达已在中国获批十多项适应证，覆盖黑色素瘤、非小细胞肺癌、食管鳞癌、头颈部鳞状细胞癌、结直肠癌、肝细胞癌、三阴性乳腺癌、MSI-H/dMMR 实体瘤、胃癌、胆道癌等癌种。 ->点击文末阅读原文，解锁完整双语新闻 No.3 / 诺和诺德口服GLP-1RA诺和忻在中国商业上市 2025年1月13日，诺和诺德宣布，口服胰高糖素样肽-1受体激动剂（GLP-1RA）诺和忻（司美格鲁肽片）在中国商业上市。 诺和忻2024年1月23日获得中国国家药监局（NMPA）批准，用于2型糖尿病患者，成为全球首个口服GLP-1RA类药物。诺和忻借助“SNAC吸收促进剂”创新技术，突破了多肽类药物难以通过胃肠吸收的壁垒，以便利的口服给药方式，帮助患者更早获益于GLP-1RA类药物，助力血糖优质达标与代谢综合管理，为中国2型糖尿病临床治疗带来创新选择。 ->点击文末阅读原文，解锁完整双语新闻 企业动态 No.1 / 最高10.55亿美金！艾伯维与先声再明达成三靶点T细胞衔接器许可选择协议 2025年1月13日，先声药业（2096.HK）宣布，旗下抗肿瘤创新药公司先声再明与艾伯维就先声再明的在研候选药物SIM0500达成许可选择协议。根据该协议条款，先声再明将从艾伯维收取首付款，最高10.55亿美金的选择性权益付款和里程碑付款，以及基于该产品在大中华区以外地区净销售额的分级特许权使用费。艾伯维有权就SIM0500在大中华地区的净销售额收取分级特许权使用费。 SIM0500是一款人源化GPRC5D-BCMA-CD3三特异性抗体，由先声再明通过其专有的T细胞衔接器多特异性抗体技术平台开发。该分子结合了低亲和力而高靶向激活的CD3抗体，以及抗G蛋白偶联受体C家族5组成员D（GPRC5D）和抗B细胞成熟抗原（BCMA）的两种抗肿瘤相关抗体。SIM0500通过多种抗肿瘤机制，表现出了针对多发性骨髓瘤（MM）细胞的强大T细胞毒性效应。目前，SIM0500正在中美两国开展针对复发或难治性MM的临床I期研究。 ->点击文末阅读原文，解锁完整双语新闻 No.2 / 再兆科眼科授权AFT在澳洲及新西兰分销老花眼候选药物BRIMOCHOL PF 2025年1月14日，兆科眼科（6622.HK）宣布与新西兰健康护理产品制造商及分销商AFT Pharmaceuticals Limited（以下简称“AFT”）就BRIMOCHOL PF签订分销及供应协议。 根据协议条款，兆科眼科有权授予AFT在澳洲及新西兰进口、分销、推广、营销及销售BRIMOCHOL PF的独家权利。作为协议的一部分，AFT将代表兆科眼科取得相关的当地药物注册。兆科眼科将收取一笔不可退还及不可抵扣的预付款，并可根据若干成就获得额外的里程碑付款。 BRIMOCHOL PF是一种不含防腐剂的每日一次瞳孔调节滴眼液，由兆科眼科与Tenpoint Therapeutics Ltd.（以下简称“Tenpoint）合作开发，拟用于矫正因老花眼而丧失的近距离视力。该产品为固定剂量卡巴胆碱（胆碱制剂）及酒石酸溴莫尼丁（α2-受体促效剂）复方，可使瞳孔收缩，产生“针孔效应”，从而使中短距离的影像更锐利。关键临床试验BRIO-II显示，BRIMOCHOL PF成功达到了预设的主要终点，在8小时近距离视力方面取得显著改善；该研究有望支持2025年上半年在美国提交BRIMOCHOL PF的新药上市申请。 ->点击文末阅读原文，解锁完整双语新闻 No.3 / 礼来斥资25亿美元收购Scorpion，囊获PI3K抑制剂资产 2025年1月13日，礼来宣布与Scorpion Therapeutics, Inc.（简称“Scorpion”）达成最终协议，礼来将收购Scorpion的PI3Kα抑制剂项目STX-478。 STX-478是一种每日一次口服的突变选择性PI3Kα抑制剂，目前正处于乳腺癌及其他晚期实体瘤的I/II期临床试验阶段。 根据协议条款，礼来将收购Scorpion。Scorpion的股东可获得高达25亿美元的现金，包括首付款和达到特定监管及销售里程碑的后续付款。作为交易的一部分，Scorpion将剥离出一个新实体，持有其员工和非PI3Kα管线资产；这家新的独立公司将由Scorpion的当前股东所有，礼来持有少数股权。 ->点击文末阅读原文，解锁完整双语新闻 全球医疗情报领导者 解锁隐藏在数据中的商业潜力  关于 G B I ” 自从2002年成立以来，GBI始终以技术为驱动，为药企、器械及行业相关服务商提供贯穿生命周期的全球药品市场竞争数据、全球行业资讯、HCPs洞察、全国医疗器械数据等商业信息与洞察，助力企业在进行战略布局和决策时，脱颖而出。历经20余年的深耕细作GBI已成为95%以上跨国药企、国内头部药企、咨询与投资机构等医疗圈灯塔用户值得信赖的长期合作伙伴。 联系我们 投稿 | 发稿 | 媒体合作 ▶ zhangxinyue13@baidu.com 数据库 | 咨询服务 | 资讯追踪 ▶ 点击左下“阅读原文”完成表单填写 点击阅读原文，解锁完整双语新闻